Business
Stoke Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
– Phase 3 EMPEROR study of zorevunersen, a first-in-class potential disease-modifying medicine for Dravet syndrome, on track to initiate in 2Q 2025 – – As of
About this update from Stoke Therapeutics, Inc.
[{"type":"text","content":"\n– Phase 3 EMPEROR study of zorevunersen, a first-in-class potential disease-modifying medicine for Dravet syndrome, on track to initiate in 2Q 2025 –\n\n– As of December 31, 2024, the Company had $246.7 million in cash, cash equivalents, and marketable securities; together with the $165 million upfront and eligible proceeds from Biogen collaboration anticipated to fund operations to mid-2028 –\n\n BEDFORD, Mass.--(BUSINESS WIRE)--\nStoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today reported financial results for the full year ended December 31, 2024 and provided business updates.\n\n“Recent milestones – including Breakthrough Therapy Designation, positive data supporting our Phase 3 dosing regimen and global regulatory alignment – have catalyzed the Dravet community and put us on track to initiate EMPEROR in the second quarter,” said Edward M. Kaye, M.D., Chief Executive Officer of Stoke Therapeutics. “The potential of zorevunersen to change the course of Dravet syndrome by addressing its underlying cause is becoming increasingly recognized. Our recent collaboration with Biogen brings complementary expertise in neurology and the global commercialization of high-value medicines for rare genetic diseases – expertise that will help us deliver faster for patients and maximize value. With a strong financial position, we are well-capitalized to advance through Phase 3 and prepare for launch readiness.”\n\nRecent Program Highlights and Additional Corporate Updates\n\n\nSeparately today, the Company announced that Dr. Edward M. Kaye has decided to step down as Chief Executive Officer of Stoke Therapeutics. After seven years of successful leadership and taking the company from a startup to a late-stage clinical development company, Dr. Kaye will transition to an advisory role and continue to serve as a Director.\n\n\nIn February, the Company entered into a collaboration with Biogen to develop and commercialize zorevunersen for the treatment of Dravet syndrome. The Company retains exclusive rights for zorevunersen in the United States, Canada, and Mexico; Biogen r...